Ligand制药 LGND 深 沪
已收盘 08-01 16:00:00 美东时间
132.72
+1.140
+0.87%
华盛通- 最 高133.19
- 今 开131.00
- 成交量 15.60万股
- 最 低 129.55
- 昨 收 131.58
- 总市值 25.61亿
- 52周最高 143.13
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 93.58
- 委 比 -68.54%
- 总股本 1929.42万
- 历史最高 248.6071
- 量 比 1.03
- 振 幅 2.77%
- 历史最低 -19.8529
- 每 手 1
- 风险率 8.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
Orchestra BioMed announced it has secured $70 million in new capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage cardiology programs. Ligand will invest $40 million, including a $15 million equity private placement, for royalties on future sales of Orchestra’s AVIM therapy and Virtue SAB. Medtronic will invest $30 million, with $10 million in equity and $20 million in a secured subordinated promissory note convertible to a...
07-31 20:01
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
Ligand Pharmaceuticals announced it will release its Q2 2025 financial results on August 7, 2025, followed by a conference call at 8:30 AM ET to discuss the results and provide a business update. The call will be accessible via phone (800) 715-9871 (US/Canada) or (646) 307-1963 (international) using conference ID 3661098, or via live/replay webcast available online. Ligand, a biopharmaceutical company, focuses on advancing high-value medicines th...
07-24 11:00
J&J boosts full-year outlook on forex tailwinds and operational performance
Johnson & Johnson (NYSE:JNJ) traded higher in the premarket on Wednesday as the healthcare giant started pharma earnings season, lifting its full-year outlook after reporting better-than-expected fina...
07-16 19:04
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.
07-10 20:13
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
Ligand Pharmaceuticals announced that its partner Pelthos Therapeutics has launched ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum, earning Ligand a $5 million milestone payment. Ligand now owns 56% of Pelthos post-merger and is entitled to a 13% royalty on ZELSUVMI sales and up to an additional $5 million in milestones. ZELSUVMI, developed using Ligand's NITRICIL™ technology, is the first topical prescription medic...
07-10 12:00
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednes...
07-09 23:06
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
Ligand Pharmaceuticals completed its merger with Channel Therapeutics to form Pelthos Therapeutics, which will begin trading on the NYSE American under the ticker "PTHS" on July 2, 2025. Pelthos plans to launch ZELSUVMI, a novel topical gel for treating Molluscum contagiosum infections, later this summer. Ligand invested $18 million in the combined company and will receive a 13% royalty on ZELSUVMI's worldwide sales. The merger also included a $5...
07-02 11:00
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
Pelthos Therapeutics Inc., formed through the merger of Channel Therapeutics and Ligand’s LNHC, will debut on the NYSE American exchange under ticker "PTHS" on July 2, 2025. The company plans to launch ZELSUVMI™, a novel topical gel for molluscum contagiosum, in July 2025. Concurrently, Pelthos secured $50.1 million in a private equity placement, including repayment of $18.8 million in prior bridge financing. The company aims to leverage its nitr...
07-02 11:00
新浪财经ESG：Ligand Pharmaceuticals Incorpora MSCI（明晟）ESG评级调降至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
06-27 07:00
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
The European Medicines Agency (EMA) has recommended the approval of nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with progressing desmoid tumors in Europe. The European Commission (EC) is expected to make a final decision by the third quarter of 2025. Nirogacestat has already been approved in the U.S. and demonstrated significant benefits in the Phase 3 DeFi trial, including improved progression-free survival and p...
06-20 12:00
